Takashi Kamikubo

This inventor holds 33 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Charged Particle Beam Technology. Top assignees: Nuflare Technology, Inc., Astellas Pharma Gmbh, Cytokinetics, Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Kamikubo. Retrieved from https://idiyas.com/inventor/takashi-kamikubo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 10)

% Patents Active = 78.8

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 3.0

ph-index = 8

Forward Citations = 202(Granted Patents)

Location History:

Kawasaki, JP (2001 - 2002)
Ibaraki, JP (2003 - 2004)
Chuo-ku, JP (2009)
Kanagawa, JP (2009 - 2010)
Numazu, JP (2013)
Yokohama, JP (2016)
Minato, JP (2020)
Tokyo, JP (1997 - 2024)

Company Filing History:

12 out of 748

Nuflare Technology, Inc.

Kabushiki Kaisha Toshiba

patents

5. 3 out of 105

Toyo Ink Mfg. Co., Ltd.

patents

6. 2 out of 223

Toyo Ink Manufacturing Company

patents

7. 2 out of 329

Yamanouchi Pharmaceutical Company Ltd.

Kotobuki Pharmaceutical Co Ltd

patents

10. 1 out of 1

Kotobuki Pharmaceutical Co., Ltd.

patent

11. 1 out of 1

Tenvie Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Charged Particle Beam

Lithography

Writing Method

Pigment Dispersing Agent

Aperture Member

Tetrahydroisoquinoline

Quinolone Derivative

Pattern Writing

Deflection Aberration

Heteroaryl Carboxamide

Multi Charged Particle Beam

Coating Composition

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741942 - Substituted pyridazine compound (2026-09-22),

2. 12655122 - Heteroaryl carboxamide compound (2026-06-16),

3. 12390536 - Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound (2025-08-19),

4. 12077519 - Heteroaryl carboxamide compound (2024-09-03),

5. 11479561 - Tetrahydroisoquinoline derivatives (2022-10-25),

6. 10699877 - Charged-particle beam writing apparatus and charged-particle beam writing method (2020-06-30),

7. 10689393 - Tetrahydroisoquinoline derivatives (2020-06-23),

8. 10259821 - Tetrahydroisoquinoline derivatives (2019-04-16),

9. 9914741 - Tetrahydroisoquinoline derivatives (2018-03-13),

10. 9343323 - Method of producing aperture member (2016-05-17),

11. 9159535 - Multi charged particle beam writing method, and multi charged particle beam writing apparatus (2015-10-13),

12. 8859997 - Charged particle beam writing apparatus and charged particle beam writing method (2014-10-14),

13. 8835881 - Drift correction method and pattern writing data generation method (2014-09-16),

14. 8629126 - Quinolone derivative or pharmaceutically acceptable salt thereof (2014-01-14),

15. 8367276 - Mask blank and method of manufacturing mask (2013-02-05),

Title: Takashi Kamikubo: A Pioneer in Pharmaceutical Innovations

Introduction

Takashi Kamikubo, based in Tokyo, Japan, is an accomplished inventor with an impressive portfolio of 30 patents. His work in the pharmaceutical field is making significant contributions to the treatment of various diseases, particularly cancer and neuromuscular disorders.

Latest Patents

Among his latest inventions are two noteworthy patents. The first introduces a heteroaryl carboxamide compound, which serves as an active ingredient for pharmaceutical compositions aimed at treating cancer linked to immune cell activation or those resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapies. This innovation demonstrates a DGK ξ (DGKzeta) inhibitory effect, showcasing its potential as a therapeutic agent for cancer treatment.

The second patent focuses on novel tetrahydroisoquinoline derivative compounds. These compounds can be utilized as active ingredients in pharmaceutical compositions for a variety of conditions, including neuromuscular disorders and musculoskeletal dysfunctions. By modulating the contractility of skeletal muscles, particularly through the troponin complex, these derivatives hold promise for treating a range of diseases characterized by muscle weakness and dysfunction.

Career Highlights

Throughout his career, Takashi Kamikubo has worked with prominent companies in the pharmaceutical industry, notably Nuflare Technology, Inc. and Astellas Pharma GmbH. His contributions have led to significant advancements in drug development and therapeutic strategies.

Collaborations

Kamikubo has collaborated with notable professionals in his field, including Hirohito Anze and Ippei Sato. These partnerships have facilitated the exchange of ideas and expertise, enhancing the effectiveness of his research and resulting in innovative pharmaceutical solutions.

Conclusion

Takashi Kamikubo's inventive spirit and dedication to advancing pharmaceutical technology have made him a key player in the innovation landscape. His research and patents continue to pave the way for breakthroughs in treatments for cancer and neuromuscular disorders, reflecting his commitment to improving patient outcomes through scientific advancements.

Profile summary based on public USPTO records.